Aquestive Therapeutics (AQST) Scheduled to Post Quarterly Earnings on Tuesday

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) will be announcing its earnings results after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Individual that wish to listen to the company's earnings conference call can do so using this link.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings data on Tuesday, March 5th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.04). The business had revenue of $13.21 million for the quarter, compared to the consensus estimate of $11.79 million. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aquestive Therapeutics Stock Performance

Aquestive Therapeutics stock traded down $0.38 during trading hours on Tuesday, reaching $3.36. 4,003,454 shares of the stock were exchanged, compared to its average volume of 2,284,417. The stock has a market cap of $246.29 million, a P/E ratio of -23.36 and a beta of 2.87. Aquestive Therapeutics has a 52-week low of $1.25 and a 52-week high of $6.23. The firm's 50 day moving average is $4.19 and its 200 day moving average is $2.84.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on AQST. Piper Sandler began coverage on shares of Aquestive Therapeutics in a report on Thursday, April 11th. They issued an "overweight" rating and a $10.00 price target for the company. JMP Securities raised their price target on shares of Aquestive Therapeutics from $8.00 to $10.00 and gave the stock an "outperform" rating in a research note on Friday, March 15th. Raymond James initiated coverage on shares of Aquestive Therapeutics in a research report on Thursday, March 28th. They issued an "outperform" rating and a $7.00 target price on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Aquestive Therapeutics currently has an average rating of "Buy" and a consensus target price of $8.00.

Insider Activity

In other news, insider Alexander Mark Schobel sold 50,000 shares of Aquestive Therapeutics stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $6.00, for a total transaction of $300,000.00. Following the sale, the insider now owns 984,476 shares in the company, valued at $5,906,856. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 8.39% of the company's stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.